Navigation Links
Pioneering Use of Mobile Technology to Conduct Clinical Trials in Emerging Economies

BRUSSELS, July 7 /PRNewswire/ -- Last week, at the fourth annual Clinical Trials in Emerging Economies conference, Margaret Ann Snowden, Director of Biostatistics and Data Management at Aeras Global TB Vaccine Foundation, and Daragh Ryan of Cmed Technology, presented a case study of the application of the latest in clinical data technology to a large Phase II clinical trial in South Africa. The presentation provided an update on how effective technology can be in promoting the development of affordable vaccine regimens for the prevention of tuberculosis (TB) worldwide.

(Logo: )

(Logo: )

In July 2009, Aeras enrolled the first subjects in a Phase II double-blind, randomized clinical trial of a TB vaccine candidate in infants in Worcester, South Africa. In this study, Aeras is using Cmed's Timaeus clinical data management platform to electronically capture data from three clinical sites in South Africa, while managing and analyzing the data from its headquarters in Rockville, Maryland USA in near real time. The Timaeus self-contained appliance technology allows clinicians and study coordinators in South Africa to capture data and perform edit checks on clinical data immediately; per study metrics to date, edit checks take an average of 0.376 seconds to run, and page turn rate has averaged 0.119 seconds. Timaeus then communicates all captured data to Aeras' US headquarters using consumer-standard, off-the-shelf mobile data cards, enabling staff at Aeras to review or report upon clinical data upon transmission.

"Aeras is an agile organization. We want the ability to make real-time, metric-based decisions on a weekly – and even daily – basis, as needed, and to position ourselves to be submission-ready on the back end," said Snowden.

When asked about the sites' experience with Timaeus over the past year, Snowden indicated that Aeras had received very positive feedback to date. In total, only 12 user calls have been placed to Cmed Technology's help desk. To prevent staff downtime, Timaeus will continue to work in the event no mobile signal is present, similar to industry-leading mobile devices. Clinicians and monitors can continue to work without interruption. When the mobile signal is restored, Timaeus automatically re-connects and communicates all data (with a full audit trail) without any user action.  

As Aeras expands its global vaccine development, Cmed Technology will continue its partnership with Aeras for ongoing advancement in the areas of trial configuration, monitoring, data management and reporting.

About Aeras Global TB Vaccine Foundation

The Aeras Global TB Vaccine Foundation is a non-profit research organization developing new tuberculosis vaccines and ensuring that they are distributed to all who need them around the world. Aeras receives funding from private foundations and governments. Aeras is based in Rockville, Maryland, where it operates a state-of-the-art manufacturing and laboratory facility, and Cape Town, South Africa. For more information, visit

About Cmed Technology Ltd

Cmed Technology has roots from Oxford University, starting in 2000 as ThirdPhase Ltd, an electronic data capture research and development company. After acquisition by Cmed in 2002, it became Cmed's technology research and development division. Currently, it directly provides its next-generation technology, Timaeus, to customers and partners to optimize clinical data management. Cmed customers currently use it to capture and manage clinical data in real-time across six continents, for a broad range of clinical trials. For more information, visit

SOURCE Cmed Technology
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. Frost & Sullivan Recognizes AOptix Technologies for its Pioneering Contribution to Security through Noninvasive Biometrics
2. 2009 Damon Runyon-Rachleff Innovation Awards granted for pioneering ideas in cancer research
3. Award for pioneering stem cell research to mend broken bones
4. WPI receives $1.2 million NIST award for pioneering study of wireless body area networks
5. WPI receives $1.4 million from NIH for pioneering work on arterial plaque and cardiovascular disease
6. Motorola Introduces Mobile Biometric Identification for Handheld Computers
7. Promptu Unveils High Accuracy Voice-to-Text Dictation for Mobile Phones at CTIA
8. Mapping a clan of mobile selfish genes
9. Texas College Police Unit Deploys BIO-key(R) Mobile Data System
10. BIO-key(R) Mobile Data and Messaging Solutions Link Nebraska Law Enforcement Agencies
11. Mobile Communication Market Opens up for Biometrics - Precise Biometrics Awarded 1st Prize at GSMA World Mobile Congress
Post Your Comments:
(Date:6/2/2016)... -- The Department of Transport Management (DOTM) of ... US Dollar project, for the , Supply and ... and IT Infrastructure , to Decatur ... of Identity Management Solutions. Numerous renowned international vendors participated in ... was selected for the most compliant and innovative solution. ...
(Date:6/2/2016)... June 2, 2016 Perimeter Surveillance ... Unmanned Systems, Physical Infrastructure, Support & Other Service  ... visiongain offers comprehensive analysis of the global ... will generate revenues of $17.98 billion in 2016. ... Inc, a leader in software and hardware technologies for ...
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing ...  3D medical LCD display is the latest premium product recently added to the range ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... 23, 2016 , ... Mosio, a leader in clinical research ... Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the ... tools, and strategies for clinical researchers. , “The landscape of how patients receive ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. , ... tests introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
Breaking Biology Technology: